Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 78.15
+2.95 (3.92%)
May 7, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 40.87 billion as of May 7, 2026. Its market cap has increased by 189.23% in one year.
Market Cap
40.87B
Enterprise Value
43.94B
Revenue
7.42B
Ranking
n/a
PE Ratio
44.75
Stock Price
78.15
Market Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 40.87B, an increase of 53.30%. That is a compound annual growth rate of 6.67%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 6, 2026 | 40.87B | 31.81% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| RemeGen | 72.21B |
| 3SBio | 55.16B |
| Biocytogen Pharmaceuticals (Beijing) | 42.51B |
| Shanghai Junshi Biosciences | 41.70B |
| Genscript Biotech | 31.53B |
| InnoCare Pharma | 27.39B |
| Duality Biotherapeutics | 23.08B |
| Keymed Biosciences | 21.30B |